1	Prevalence and risk factors of disability and anxiety in a retrospective cohort of
2	432 survivors of Coronavirus Disease-2019 (Covid-19) from China
3	
4	Siyi Zhu ^{1,2,¶} ; Qiang Gao ^{1,2,} ¶; Lin Yang ^{1,2,} ¶; Yonghong Yang ^{1,2,} ¶; Wenguang Xia ⁴ ; Xiguo
5	Cai ⁵ ; Yanping Hui ⁶ ; Di Zhu ⁷ ; Yanyan Zhang ⁸ ; Guiqing Zhang ⁹ ; Shuang Wu ¹⁰ ; Yiliang
6	Wang ¹¹ ; Zhiqiang Zhou ¹² ; Hongfei Liu ¹³ ; Changjie Zhang ¹⁴ ; Bo Zhang ¹⁵ ; Jianrong
7	Yang ¹⁶ ; Mei Feng ³ ; Zhong Ni ³ ; Baoyu Chen ¹ ; Chunping Du ^{1,2} ; Hongchen He ^{1,2} ; Yun
8	Qu ^{1,2} ; Quan Wei ^{1,2} ; Chengqi He ^{1,2,17,¶*} ; Jan D. Reinhardt ^{17,18,19,20,} ¶*.
9	
10	
11	¹ Rehabilitation Medical Center, West China Hospital, Sichuan University, Chengdu,
12	China.
13	² Rehabilitation Medicine Key Laboratory of Sichuan Province, Sichuan University,
14	Chengdu, China.
15	³ Department of Critical Care Medicine, West China Hospital, Sichuan University,
16	Chengdu, China.
17	⁴ Hubei Hospital of Integrated Traditional Chinese and Western Medicine, Wuhan,
18	Hubei, China.
19	⁵ Henan Provincial People's Hospital, Zhengzhou, Henan, China.
20	⁶ The Second Affiliated Hospital, Medical College of Xi'an Jiaotong University, Xian,
21	Shanxi, China.
22	⁷ Zhejiang provincial People's Hospital, Hangzhou, Zhejiang, China.
23	⁸ Qilu Hospital of Shandong University, Jinan, Shandong, China.

- ⁹ The First Affiliated Hospital, School of Medicine, Shihezi University, Xinjiang, China.
- ¹⁰ The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
- ¹¹ Chongqing Three Gorges Central Hospital, Chongqing, China.
- ¹² Inner Mongolia Autonomous Region Baotou Central Hospital, Baotou, China.
- ¹³ General Hospital of General Bureau of Agricultural Reclamation of Heilongjiang
- 29 Province, Harbin, China.
- ¹⁴ The Second Xiangya Hospital of Central South University, Changsha, China.
- ¹⁵ Nanchong central hospital, Nanchong, Sichuan, China.
- ¹⁶ Garze People's Hospital, Garze Tibetan Autonomous Prefecture, Sichuan, China.
- ¹⁷ Institute for Disaster Management and Reconstruction of Sichuan University and
- Hong Kong Polytechnic University, Sichuan University, Chengdu, China.
- ¹⁸ Swiss Paraplegic Research, Switzerland.
- ¹⁹ Department of Health Sciences and Medicine, University of Lucerne, Switzerland.
- ²⁰ Committee for Rehabilitation Disaster Relief, International Society for Physical and
- 38 Rehabilitation Medicine, Geneva, Switzerland.
- 39
- ⁴⁰ [¶]S Zhu, Q Gao, L Yang, Y Yang, Q Wang, C He and JD Reinhardt contributed equally

41 and share first authorship.

- 42
- ⁴³ *Correspondence to: Prof Chengqi He MD, Rehabilitation Medical Center, West China
- 44 Hospital, No.37 Guoxue Alley, Wuhou District, Chengdu, China hxkfhcg@126.com

- 45 or Prof Jan D. Reinhardt PhD, Institute for Disaster Management and Reconstruction of
- 46 Sichuan University and Hong Kong Polytechnic University, Sichuan University, 122
- 47 Huanghe Zhong Lu, Chengdu 610041, Sichuan, China jan.reinhardt@paraplegie.ch.

48 Abstract

- 49
- 50 **Objective:** To estimate the prevalence of disability and anxiety in Covid-19 survivors at

51 discharge from hospital and analyze relative risk by exposures.

52 **Design:** Multi-center retrospective cohort study.

53 **Setting**: Twenty-eight hospitals located in eight provinces of China.

54 **Methods**: A total of 432 survivors with laboratory-confirmed SARS CoV-2 infection

55 participated in this study. At discharge, we assessed instrumental activities of daily living

⁵⁶ (IADL) with Lawton's IADL scale, dependence in activities of daily living (ADL) with the

57 Barthel Index, and anxiety with Zung's self-reported anxiety scale. Exposures included

comorbidity, smoking, setting (Hubei vs. others), disease severity, symptoms, and length

of hospital stay. Other risk factors considered were age, gender, and ethnicity (Han vs.

- 60 Tibetan).
- 61 **Results:** Prevalence of at least one IADL problem was 36.81% (95% CI: 32.39-41.46).

62 ADL dependence was present in 16.44% (95% CI: 13.23-20.23) and 28.70% (95% CI:

63 24.63-33.15) were screened positive for clinical anxiety. Adjusted risk ratio (RR) of IADL

64 limitations (RR 2.48, 95% CI: 1.80-3.40), ADL dependence (RR 2.07, 95% CI 1.15-3.76),

- and probable clinical anxiety (RR 2.53, 95% Cl 1.69-3.79) were consistently elevated in
- 66 survivors with severe Covid-19. Age was an additional independent risk factor for IADL

67 limitations and ADL dependence; and setting (Hubei) for IADL limitations and anxiety.

⁶⁸ Tibetan ethnicity was a protective factor for anxiety but a risk factor for IADL limitations.

69 **Conclusion:** A significant proportion of Covid-19 survivors had disability and anxiety at

discharge from hospital. Health systems need to be prepared for an additional burden

resulting from rehabilitation needs of Covid-19 survivors.

Keywords: COVID-19; Rehabilitation; Disability; Activities of Daily Living; Mental Health;
 Anxiety.

74

75 Introduction

With rapidly increasing numbers of confirmed cases and deaths caused by the 76 77 Coronavirus Disease-2019 (Covid-19) pandemic, clinical outcomes research has almost exclusively focused on disease progression and mortality[1]. With the case fatality rate 78 79 estimated to lie somewhere between 0.56 and 9.38 percent globally (95% prediction interval, $I^2 = 100\%$, [2] it is obvious however that a vast majority of people actually 80 survive Covid-19. A substantial proportion of survivors have experienced severe disease 81 episodes requiring hospitalization and - in a considerable number of cases - intensive 82 care including mechanical ventilation[3]. In addition, contracting a potentially fatal 83 disease is stressful and can cause anxiety and other psychiatric manifestations in many 84 patients.[4] It would be naïve to assume that health problems just disappear upon 85 discharge from acute care or when viral RNA is no longer detectable, and equally naïve 86 to take planned and systematic follow up of patients for granted [5, 6] Yet, the burden of 87 88 disease resulting from physical and psychological sequelae of Covid-19 in patients

89 surviving the disease as well as potential long-term adverse effects from treatments 90 including steroids such as Dexamethasone are just beginning to catch attention [7, 8]. Globally, respiratory infections and tuberculosis assume already the fourth rank of all 91 diseases in terms of disability adjusted life years (DALYs) and the 17th rank in years 92 lived with disability (YLD). In infectious disease, they sadly rank first and second, 93 94 respectively.[9, 10] Covid-19 will increase this burden considerably and cause longer 95 term mental and physical health problems, work disability, and reduced quality of life in survivors, frontline health professionals, and those guarantined.[11, 12] What we know 96 from the 2002/2003 Severe Acute Respiratory Syndrome (SARS) epidemic is not 97 98 encouraging. In Hong Kong for example, about 80 percent of SARS survivors still needed follow-up treatment two years after the outbreak had been contained.[13] 99 100 The number of patients needing follow-up care and rehabilitation due to Covid-19 will be 101 unprecedented. Countries need to consider and plan for this additional long-term challenge to the health system. It is important to understand risk factors for disability and 102 103 mental health problems now in order to direct scarce resources and meet windows of 104 opportunity for treatment. This study makes a first attempt to address this issue. We 105 aimed to (1) estimate the prevalence of disability and anxiety in Covid-19 survivors from eight Provinces/centrally governed municipalities of the PR China at discharge from 106 acute inpatient treatment, and (2) investigate relative risk of adverse outcomes by 107 various determinants including gender, age, comorbidity, setting, ethnicity and disease 108 109 severity. Prevalence estimates are important to gain insight in the potential number of patients needing follow-up care. Analyzing risk factors is instrumental in identifying 110 vulnerable groups and allocating resources for early interventions. 111

112 Methods

113 Study design

114 We conducted a multi-center retrospective cohort study. The study protocol was

approved by the ethics committee of West China Hospital, Sichuan University (2020-

116 273).

117 Subjects

118 Four hundred and thirty-two Covid-19 survivors were surveyed who had received

treatment in 28 designated hospitals in Hubei, Sichuan, Guizhou, Henan, Neimenggu

120 (inner Mongolia), Shandong, Hainan, and Chongqing from January 18 to March 15,

121 2020 and gave informed consent. Included were adults (≥ 16 years) who had laboratory-

122 confirmed SARS coronavirus-2 (SARS CoV-2) infection and met the diagnostic criteria

123 of the Novel Coronavirus Pneumonia Diagnosis and Treatment Program (Trial Version

124 7) issued by the National Health Commission of the PR China (Third edition).[14]

125 Survivors further needed to be in stable medical condition and have been discharged or

be about to be discharged from the participating centers. Excluded were patients with

127 pneumonia caused by other types of coronaviruses, seasonal influenza, bacteria, or

128 other not SARS CoV-2 etiology.

129 Patients were contacted by health professionals who were in charge of their treatment.

130 All health professionals were instructed on implementation of the study protocol,

131 informed consent procedures, and possible sources of bias by videoconference.

132 Measures

133 Outcomes: Outcomes were disability and anxiety. Cut off date for outcome assessment

134 was April 7, 2020. Disability was measured in two ways: (1) Limitations in instrumental

activities of daily living (IADL) were assessed with the Lawton IADL scale[15] and

classified into no limitations vs. one or more limitations (primary outcome). An index of 136 137 the number of reported IADL limitations was also created. (2) Dependence in activities of daily living (ADL) was measured with the Barthel Index[16] and classified into severe or 138 moderate dependence vs. mild dependence/independence.[17] Anxiety was evaluated 139 140 with Zung's Self-Reported Anxiety Scale[18] (SAS) and classified into probable clinical 141 anxiety disorder vs. not according to a conservative cutoff recommended for 142 research.[19] Outcome data were patient-reported and collected with an online questionnaire. 143 *Risk factors:* Clinical and demographic data were extracted from hospital records by 144

145 participating health professionals. Current smoking status was self-reported by 146 participants. Demographic data included age, gender, province (Hubei vs. others), and 147 ethnicity (Han vs. Tibetan). Having received treatment in Hubei was considered a risk 148 factor because of the particular situation in Hubei which was the epicenter of the epidemic in China representing about 80 percent of confirmed cases. Ethnicity was 149 150 included as a significant proportion of the sample from Sichuan was from the Tibetan 151 ethnic group, and belonging to a minority ethnic group is known to be associated with 152 health outcomes in other disease. Clinical data included comorbidity, disease severity, symptoms at admission, scope of pneumonia, and length of inpatient stay. Recorded 153 comorbid conditions included COPD, chronic bronchitis, pulmonary fibrosis, 154 hypertension, diabetes, cardiovascular disease, kidney disease, hepatitis, rheumatism, 155 156 and gout. Degree of Covid-19 severity was classified according to the Chinese standard.[14] Patients were defined as severe cases when they met one of the following 157 criteria at any time during hospitalization: acute respiratory distress, respiratory rate \geq 30 158 breath/min; pulse oxygen saturation (SpO2) ≤93% at rest; arterial blood partial pressure 159

of oxygen/fraction of inspired oxygen (PaO2/FiO2) ≤300 mmHg (1 mmHg = 0.133 kPa);
 respiratory failure requiring mechanical ventilation; septic shock; failure of other organs
 requiring ICU treatment. Symptoms recorded at admission included fever, cough,
 diarrhea, fatigue and pain. Scope of pneumonia was noted as uni- or bilateral per
 radiographic findings. Data on length of hospital stay were available for 408 patients
 (94.44%).

Sample size calculation

Sample size to detect a two-fold relative risk for reporting one or more IADL limitations in the severe disease group as compared to the non-severe group with a power of 80% and alpha error of 5% was estimated under the following assumptions: 0.2 ratio of severe to non severe group (based on patients received at our own center), 15 percent prevalence of outcome in non-severe group. This yielded a minimal sample size of 401 (67 severe, 334 non-severe).

173 Analysis

Prevalence of limitations in IADL, ADL dependence, and anxiety for the full sample and 174 175 by disease severity were provided with 95% confidence intervals (CIs) estimated from logistic regression. Risk ratios (RR) and 95% CIs for gender, age group (<= 50, 50-60, > 176 60 years), province (others vs. Hubei), ethnicity (Han vs. Tibetan), comorbid health 177 178 conditions (none, one, multiple), disease severity (non-severe vs. severe), symptoms 179 (<=1, >1) at admission, and infection scope (unilateral vs. bilateral) were estimated with 180 log-linear Poisson regression with robust standard errors. [20] Since longer time of being hospitalized could increase anxiety, length of hospital stay was included in the anxiety-181 182 model in addition. For each outcome unadjusted RR and RR adjusted for all other

potential risk factors evaluated were provided. Zero-inflated Poisson (ZIP) regression 183 184 was used to estimate the effect of risk factors on the extent of IADL limitations. ZIP regression assumes that there are two groups in the population from which the data are 185 sampled, one which always has zero counts, and one which may have zero or higher 186 counts. Young people with non-severe disease who have no comorbidity may never 187 develop IADL limitations, while other groups may develop (additional) IADL limitations 188 due to factors associated with disease progression. ZIP regression simultaneously 189 performs logistic and Poisson regression making two types of predictions: (1) prediction 190 of excess zeros assuming a binary dependent variable (no IADL limitations vs. one or 191 192 more), (2) prediction of the count portion (number of experienced IADL limitations). 193 Predictors included in the logistic part were the following background factors: age group 194 and interaction of age and disease severity, province, ethnicity, smoking, and comorbid 195 conditions. Predictors included in the count part were potential drivers of disease consequences: disease severity, interaction of age and disease severity, symptoms, and 196 197 infection scope. Vuong's test confirmed fit of the ZIP model. 198 All analyses were performed with Stata 14 (Stata corporation, Texas, USA).

199 **Results**

Demographic and clinical characteristics and prevalence of outcomes of the study participants are provided in Table 1. Median age was 49 (IQR 35-60) and 49% were female. About one third of the study participants were classified as severe cases. Fever, cough, and fatigue were the most common symptoms at admission. A majority had no pre-existing health condition and were non-smokers. Patients with severe Covid-19 were older, were more often from Hubei and belonged to the Han majority, presented with

more symptoms, had more often bilateral pneumonia, and stayed in the hospital for a
longer time. More pre-existing health conditions were present in severe cases, but the
percentage of smokers was lower. Over one third of Covid-19 survivors had at least one
IADL limitation, about 15 percent had at least moderate ADL dependence, and six
percent were severely dependent. Probable clinical anxiety disorder was found in about
29 percent of the population. Prevalence of all outcomes was more than four times
higher in survivors of severe Covid-19 than in those with non-severe disease.

213 Table 1. Demographic and Clinical Characteristics of study participants (I) and prevalence of outcomes (II)

I Demographic and clinical	All participants	By disease severity	
1. Demographic and clinical characteristics	(N=432)	non-severe	severe
		(n=285, 65.97%)	(n=147, 34.03%)
Female sex – no./total no. (%)	207/432 (47.92)	138/285 (48.42)	69/147 (46.94)
Age			
Median (IQR) in years	49 (35-60)	45 (32.5-54.5)	57 (47-68)
Distribution – no./total no. (%)			
< 50	218/431 (50.58)	173/284 (60.92)	45/147 (30.61)
50-60	108/431 (25.06)	69/284 (24.30)	39/147 (26.53)
> 60	105/431 (24.36)	42/284 (14.79)	63/147 (42.86)
Province – no./total no. (%)			
Hubei	169/432 (39.12)	73/285 (25.61)	96/147 (65.31)
Sichuan	162/432 (37.50)	144/285 (50.53)	18/147 (12.24)
Chongqing	38/432 (8.80)	29/285 (10.18)	9/147 (6.12)
Henan	30/432 (6.94)	15/285 (5.26)	15/147 (10.20)
Guizhou	24/432 (5.56)	17/285 (5.96)	7/147 (4.76)
Other	9/432 (2.08)	7/285 (2.46)	2/147 (1.36)

Han	360/432 (83.33)	220/285 (77.19)	140/147 (95.24)
Tibetan	72/432 (16.67)	65/285 (22.81)	7/147 (4.76)
Smoking history, yes – no./total no. (%)	62/432 (14.35)	46/285 (16.14)	16/147 (10.88)
Pre-existing comorbidity – no./total no.			
(%)			
none	300/432 (69.44)	226/285 (79.30)	74/147 (50.34)
one	79/432 (18.29)	37/285 (12.98)	42/147 (28.57)
multi	53/432 (12.27)	22/285 (7.72)	31/147 (21.09)
Symptoms on admission – no./total no.			
(%)			
Fever	249/432 (57.64)	125/285 (43.86)	124/147 (84.35)
Cough	257/432 (59.49)	139/285 (48.77)	118/147 (80.27)
Fatigue	153/432 (35.42)	70/285 (24.56)	83/147 (56.46)
Pain	68/432 (15.74)	40/285 (14.04)	28/147 (19.05)
Diarrhea	46/432 (10.65)	24/285 (8.42)	22/147 (14.97)
Bilateral infection scope ^{&} - no./total no.	362/432 (83.80)	221/285 (77.54)	141/147 (95.92)
(%)			
Length of hospital stay [§]			
Median (IQR) in days	18 (12-25)	15 (11-22)	23 (15.5-31.61)
Distribution – no./total no. (%)			
1-14 days	160/408 (39.22)	130/268 (48.51)	30/140 (21.43)
>14 days	248/408 (60.78)	138/268 (51.49)	110/140 (78.57)
Discharge Destination [§] - no./total no. (%)			
Discharged home	278/412 (67.48)	215/269 (79.93)	63/143 (44.06)
Discharged to 14-day quarantine	128/412 (31.07)	52/269 (19.33)	76/143 (53.15)
Referred to other hospital	6/412 (1.46)	2/269 (0.74)	4/143 (2.80)
Mechanical Ventilation-no./total no. (%)			
No	395/411 (96.11)	268/268 (100.00)	127/143 (88.81)

Yes	16/411 (3.89)	0/268 (0.00)	16/143 (11.19)
II. Outcomes*			
Disability, percent (95% CI)			
One or more IADL limitations	36.81 (32.39-41.46)	18.25 (14.18-	72.79 (65.04-
		23.16)	79.37)
Moderate ADL dependence	16.44 (13.23-20.23)	6.32 (4.01-9.80)	36.05 (28.71-
			44.11)
Severe ADL dependence	5.56 (3.75-8.15)	2.46 (1.17-5.06)	11.56 (7.31-17.82)
Anxiety, percent (95% CI)	28.70 (24.63-33.15)	13.33 (9.86-17.80)	58.50 (50.38-
			66.19)

[§]Scope of pneumonia as confirmed by radiography. [&]For 24 (5.56%) patients discharge date had not been

entered in the data form. *Confidence intervals estimated from logistic regression. CI = confidence

216 interval. IADL = instrumental activities of daily living. ADL = activities of daily living.

217

Results on risk factors for disability and anxiety are displayed in Fig 1 and 2 (for detailed 218 estimates see S1-3 Tables). Risk ratios for reporting at least one IADL limitation (Fig 1, 219 upper panel) were increased in the older age groups, particularly in survivors aged older 220 than 60 years, in patients from Hubei, and in survivors with severe Covid-19. The 221 222 adjusted model also showed an elevated relative risk in survivors from the Tibetan ethnic group. Only in unadjusted models was the relative risk of having one or more 223 224 IADL limitations clearly elevated in survivors with comorbidities, in patients with more 225 symptoms at admission, and in those with bilateral infections. Both in unadjusted and adjusted models, the relative risk for ADL dependence (Fig 1 lower panel) was 226 consistently increased in Covid-19 survivors aged older than 60 years, and in 227 participants with severe disease course and more symptoms. All individual risk ratios 228

were higher in unadjusted models. Setting, comorbidity, and infection site played a rolein unadjusted analysis only.

231

Fig 1. Disability (IADL limitations and ADL dependence) in relation to potential risk 232 233 factors. Risk ratios and 95% confidence intervals. Estimated from log-linear Poisson regression with robust standard errors; unadjusted risk ratios are estimated from 234 univariable model for the effect of the respective predictor on the outcome, adjusted risk 235 236 ratios are estimated from multivariable model containing all potential risk factors. IADL = Instrumental Activities of Daily Living. ADL = Activities of Daily Living.CI=confidence 237 interval. Note: In the case of ADL dependence, the upper limit of the confidence interval 238 for the unadjusted estimate of age > 60 years has been truncated for better readability of 239 the other effects (see S1-3 Tables for details). Adjusted model and unadjusted model for 240 241 age have been estimated for 431 cases (because of one missing date of birth).

242

Fig 2. Probable clinical anxiety in relation to potential risk factors. Risk Ratios and 243 244 95% confidence intervals. Estimated from log-linear Poisson Regression with robust 245 standard errors; unadjusted risk ratios are estimated from univariable model for the effect of the respective predictor on the outcome, adjusted risk ratios are estimated from 246 multivariable model containing all potential risk factors. The adjusted model has been 247 estimated for 407 cases (because of missing information regarding length of stay for 24 248 cases and one case with missing date of birth). [&]Unadjusted model estimated for 407 249 cases (because of missing information regarding length of stay for 24 cases and one 250 case with missing date of birth). Cl=confidence interval. 251

252

253 Having severe Covid-19 was the strongest risk factor for probable clinically relevant 254 anxiety, followed by having received treatment in Hubei province (Fig 2). In turn, belonging to the Tibetan group was associated with a largely decreased relative risk of 255 anxiety. There was a trend for an increased relative risk of anxiety in survivors who had 256 stayed in the hospital for more than 14 days. Older age, comorbidity, symptoms, and 257 258 scope of pneumonia played a role in unadjusted analysis only. 259 Table 2 show the results of the ZIP regression of the number of IADL limitations on risk factors. Hospitalization in Hubei, Tibetan ethnicity, and multi-comorbidity were 260 associated with lower odds of having a zero count of IADL limitations. For all age 261 262 groups, odds for having zero IADL limitations were decreased in people with severe Covid-19. This effect became however smaller with increasing age. Disease severity, its 263 264 interaction with age, and symptoms were associated with a greater number of health 265 problems. The joint effect of age and degree of severity of Covid-19 on the number of IADL limitations from both parts of the model is illustrated in Fig 3. In all age groups 266 having a severe course of Covid-19 was associated with a higher number of self-267 268 reported IADL limitations. Point estimates for survivors with non-severe and those with 269 severe disease were however closer in the oldest age group. Cls for the number of IADL 270 limitations in participants with non-severe and those with severe Covid-19 moved closer in both older age groups and overlapped in survivors aged 61 years and older. 271 272 273 Table 2. Results from zero-inflated Poisson regression of number of IADL limitations on potential risk factors

274 (**n=431**)

I. Excess zeros: Prediction of having no IADL limitation	OR (95% CI)	SE	Z
Age			

< 50	1 (reference)		
50-60	0.66 (0.24-1.78)	0.51	-0.82
> 60	0.04 (0.01-0.10)	0.54	-6.19
Disease severity and age group			
non-severe and < 50 years old	1 (reference)		
severe and < 50 years old	0.06 (0.02-0.17)	0.51	-5.43
non-severe and 50-60 years old	1 (reference)		
severe and 50-60 years old	0.11 (0.04-0.32)	0.56	-4.02
non-severe and > 60 years old	1 (reference)		
severe and > 60 years old	0.34 (0.10-1.16)	0.62	-1.72
Province			
Other provinces	1 (reference)		
Hubei	0.09 (0.04-0.19)	0.37	-6.46
Ethnicity			
Han	1 (reference)		
Tibetan	0.16 (0.06-0.41)	0.49	3.78
Smoking history			
no	1 (reference)		
yes	1.78 (0.67-4.75)	0.50	1.15
Comorbid conditions			
none	1 (reference)		
one	0.65 (0.29-1.43)	0.41	-1.08
multi	0.33 (0.12-0.90)	0.51	-2.16
II. Count: Number of IADL limitations	IRR (95% CI)	SE	Z
Disease severity (reference: non-severe)			
non severe	1 (reference)		
severe	1.64 (0.97-2.80)	0.45	1.84

Disease severity and age group			
non-severe and < 50 years old	1 (reference)		
non-severe and 50-60 years old	1.76 (0.99-3.15)	0.52	1.92
non-severe and > 60 years old	2.91 (1.78-4.77)	0.73	4.24
severe and < 50 years old	1 (reference)		
severe and 50-60 years old	1.34 (1.03-1.74)	0.18	2.21
severe and > 60 years old	1.65 (1.33-2.05)	0.18	4.52
Symptoms, number			
<= 1	1 (reference)		
>1	1.34 (1.10-1.62)	0.13	2.98
Infection scope			
Unilateral	1 (reference)		
Bilateral	1.19 (0.89-1.61)	0.18	1.16

275 OR = odds ratio, CI = confidence interval, SE = standard error of coefficient, z = standardized coefficient, IRR =

276 incidence rate ratio, IADL = instrumental activities of daily living.

277

Fig 3. Effect of the interaction of age and disease severity on the number of 278 predicted IADL problems (triangles) with 95% confidence intervals (capped lines). 279 280 Estimated from zero-inflated Poisson regression. Predictions are adjusted for other factors in the model. Predictors included in the logistic part (excess zeros) were the 281 following: age group, interaction of age and disease severity, setting (Hubei vs. other 282 province), Tibetan ethnicity (reference: Han), smoking history, and comorbid conditions. 283 Predictors included in the count part were: disease severity, interaction of age and 284 disease severity, symptoms, and infection scope. The model has been estimated for 431 285 cases (because of one missing date of birth). 286

288 **Discussion**

This retrospective cohort study found a considerable prevalence of functional limitations 289 290 and dependence as well as anxiety in Covid-19 survivors at about time of discharge from acute inpatient treatment. Disease severity was a major independent risk factor for 291 292 all outcomes. Age was an additional risk factor for both disability outcomes, and setting 293 (Hubei) for IADL limitations and anxiety. Tibetan ethnicity was a strong protective factor for anxiety but a risk factor for IADL limitations when it was adjusted for covariates. 294 295 Demographic and clinical characteristics of the study population were comparable to 296 other reports on Covid-19 patients from China [1, 21] with two exceptions: a higher 297 percentage was classified as severe cases and current smoking was more prevalent in 298 the non-severe disease group. An explanation for the higher percentage of severe cases 299 in the present study is that the applied criteria for classifying Covid-19 cases as severe 300 by the National Health Commission of the PR China are more liberal than the criteria for 301 severe community-acquired pneumonia by the American Thoracic Society and Infectious Disease Society of America[22] used by Guan et al.[21] The lower prevalence of 302 303 smokers in participants with severe disease was unexpected and contradicts previous 304 evidence in this regard.[21] A possible explanation is that current smoking status was self-reported and participants with more severe disease outcomes did not reveal their 305 true smoking status, perhaps for fear of being stigmatized and held responsible for 306 contracting SARS CoV-2 or the severity of Covid-19. 307 We found a high prevalence of disability and anxiety, particularly in severe cases. 308

Almost three quarters of severe Covid-19 survivors experienced at least one IADL

problem and more than one third had at least moderate ADL dependence. The six

percent of the overall sample with severe ADL dependence are of particular concern 311 312 since severe functional dependence has been a reliable predictor of mortality in populations with other health conditions.[23] No other original study directly investigated 313 disability outcomes related to Covid-19 so far. Follow up studies of SARS and Middle 314 315 East Respiratory Syndrome (MERS) survivors have however shown that decreased exercise capacity and distance walked, fatigue, sleeping problems, shortness of breath, 316 317 reduced self-rated health, work disability, and structural damage (e.g. osteonecrosis) from corticosteroids were prevalent in survivors even years after onset of symptoms.[11, 318 24, 25] In addition, access to health care, quality of services, and employment 319 320 opportunities of former SARS patients were compromised by enduring stigma[13, 26]. 321 Our findings imply that a large proportion of Covid-19 survivors, particularly those who experienced severe disease episodes are in need of follow up care and rehabilitation 322 323 services. This proportion may be reduced by the integration of early rehabilitation interventions into acute care[27, 28]. 324 Probable clinical anxiety disorder was found in one third of the overall sample and its 325 326 prevalence was almost four-fold increased in severe as compared to non-severe cases. 327 Previous studies on mental health in the Covid-19 pandemic have been conducted in 328 the general population [29, 30] and health professionals [31] but not in the patient population. Studies in SARS survivors have however reported highly elevated long-term 329 psychiatric morbidity[32] and demonstrated adverse effects on the mental health of 330 331 caregivers.[11] Our findings point to the need of psychological counseling during acute care and mental health follow-up in many Covid-19 survivors to mitigate suffering and 332 prevent the manifestation of psychiatric disorders. 333

Major risk factors for mortality due to Covid-19[1, 33] were also major risk factors of 334 335 disability: older age and severe disease course both independently increased the relative risk of IADL limitations and ADL dependence. However, comorbidity[34] had an 336 adverse effect on disability outcomes in unadjusted analysis only. Though attenuated, 337 disease severity continued to play a major role when it was adjusted for age, co-338 339 morbidity, and other potential confounders demonstrating an additional effect of Covid-340 19 when other known risk factors for disability were held statistically constant. In all age groups having severe Covid-19 was associated with a higher number of self-reported 341 IADL limitations. For survivors aged over 60 years we found that the extent of IADL 342 343 limitations was more similar in those with non-severe and severe Covid-19 than in the 344 other age groups. Accordingly, the oldest participants with non-severe Covid-19 were more similar to survivors with severe disease in the younger age groups. There are two 345 possible explanations for this phenomenon that deserve further scrutiny: First, older 346 people have already more activity limitations before they acquire Covid-19. Second, a 347 non-severe disease course has a greater effect on IADL limitations for them. 348 349 Persistence of this effect when it was adjusted for comorbidity speaks for the latter 350 explanation. Having been treated in hospitals of Hubei province where Covid-19 spread 351 first and overwhelmed an unprepared health system was furthermore associated with adverse disability outcomes, particularly IADL limitations. Moreover, belonging to the 352 Tibetan ethnic minority predicted worse IADL outcomes when it was controlled for other 353 354 potential risk factors. Given that the Tibetan population of Sichuan province mainly lives in rural, mountainous areas, both findings point at the role that environmental factors 355 including the availability and accessibility of targeted services play in the disablement 356 process.[35] Our findings indicate that priority in rehabilitation resource allocation should 357

be given to patients with severe disease course, older people, and those living in
 environments with restricted accessibility of services.

Regarding anxiety, outstanding independent risk factors were severity of Covid-19 and 360 setting, i.e. having been hospitalized in Hubei province. Apart from the specific situation 361 in hospitals in Hubei, insecurity about causes, transmission patterns, and prognosis 362 when Covid-19 first occurred likely contributed to this finding. Moreover, we found a 363 364 trend for longer length of hospital stay being independently associated with increased relative risk of anxiety. In contrast to disability outcomes, Tibetan ethnicity was a 365 consistent protective factor in unadjusted as well as adjusted models of anxiety. 366 367 Possible explanations are cultural factors including larger families (due to the non application of China's one child policy to this group) and greater social cohesion and 368 369 support. This finding needs further exploration. Our results point towards heightened need for psychological support in patients who experienced severe disease episodes 370 and people from areas hardest hit by the Covid-19 pandemic. 371

372 Study Limitations

373 The present study has limitations. First, baseline data for the outcomes analyzed here 374 were not available. Because of this we cannot rule out that patients had disability or anxiety before they contracted Covid-19, indeed having disability may have made 375 people more vulnerable to the disease [36-38]. However, most patients first presented 376 377 already with severe symptoms and baseline information collected before admission is rare in any disease. Baseline information on comorbidity is thus as close as we get to 378 379 baseline disability and the effects of disease severity on outcomes remained consistent when adjusted for baseline comorbidity in our analysis. Second, we may be criticized for 380 not having employed some kind of control group. An appropriate control group for the 381

effects and population under investigation is however difficult to define and to establish. 382 383 Age and gender matched general population controls are surely not appropriate because of the lack of hospitalization. Investigating patients who have been hospitalized 384 for some other disease would not help disentangle the effects of disease and 385 hospitalization. Quarantined persons suspected for Covid-19 or those treated at home 386 may make up an interesting comparator but are difficult to access. We believe that our 387 388 comparison of patients with severe and non-severe Covid-19 nonetheless provides initial evidence for the potential impact of the disease and is an important starting point in 389 investigating this population's rehabilitation needs. Third, outcome data were self-390 391 reported by patients due to the lack of options for objective measurement. Survivors thus may have under- or overestimated their physical abilities. Patient-reported outcome 392 393 measures have however not been used in this population before to the best of our knowledge, making it difficult to appraise if and to what degree this kind of problem 394 existed. Fourth, psychiatric confirmation of anxiety in those screened positive was not 395 possible. Fifth, this study evaluated outcomes at discharge and conclusions about 396 longer-term prevalence, spontaneous recovery, and chronic manifestations cannot be 397 drawn at this point and further follow-up of the cohort is therefore indicated. 398

399 **Recommendations**

In spite of these limitations, there are several recommendations that can be derived from
our findings. First, awareness about possible functional and psychological
consequences of Covid-19 needs to be raised in patients, care providers, and health
policy makers[28]. Second, early psychological[39] and pulmonary rehabilitation
interventions including mobilization and exercise[27, 28, 40] which have been
investigated in other health conditions could be effective and important to meet

therapeutic windows; consequently their application (besides pharmacological 406 407 treatments) needs to be studied in the population of Covid-19 patients, particularly those with severe disease. Third, this involves a better integration of primary care and 408 psychiatric and rehabilitation services which is unfortunately lacking in many lower as 409 well as higher resourced countries including China.[41] Fourth, systematic community 410 follow up and two-way referral systems between community health centers and 411 specialized hospital units, another weak point of many health systems, need to be 412 strengthened.[41] Fifth, we recommend that future prospective cohort studies in Covid-413 19 survivors include functional and psychiatric outcomes. 414

415 **Conclusion**

A significant proportion of Covid-19 survivors had disability and anxiety at discharge
from hospital. Disease severity was the only independent risk factor with consistent
adverse effects on all outcomes. Health systems need to be prepared for an additional
long-term burden due to Covid-19. This includes raising awareness about mental and
physical health problems of survivors, early interventions, strengthening medical follow
up, and increasing physical and psychological rehabilitation capacity.

Author contributions

CH, SZ and JR had full access to all of the data in the study and take responsibility for
the integrity of the data and the accuracy of the data analysis. CH, SZ, QG, LY, QW, YY
and JR designed the study. WX, XC, YH, DZ, YZ, GZ, SW, YW, ZZ, HL, CZ, BZ, JY, MF,
ZN, BC, CD, and HH collected and processed the data. JR, SZ, QG, CH, and YY
interpreted the data. JR performed the statistical analysis and wrote the first draft of the

428 manuscript. All other authors revised the manuscript for critical content. All authors
429 reviewed and approved the final submitted version.

430 Acknowledgment

We thank all the hospital staff members and coordinators under the CSPRM Covid-19 431 432 network for their efforts in collecting the information that was used in this study; Liangjiang Huang (Tongji Hospital, Tongji Medical College, Huazhong University of 433 Science and Technology), Xu Qin (No.3 People's Hospital of Chengdu), Minging Li 434 435 (Dazhou Central Hospital), Kehui Hu (Suining Central Hospital), and Jinling Zhang (West 436 China Second University Hospital, Sichuan University) for their dedication to data entry and verification; Prof. Deving Kang (Epidemiologist, West China Hospital, Sichuan 437 438 University) and Mrs. Rouyue Fang (Statistician, Industrial and Commercial Bank of China) for their assistance in initial data extraction and processing; all the patients who 439 440 consented to provide their data for analysis and the medical staff members who are at 441 the frontline caring for patients with Covid-19. We would like to thank Prof. Dr. Gerold Stucki and Cristiana Baffone for constructive comments on an earlier version of the 442 manuscript. 443

444 Funding

This study was funded by the National Natural Science Foundation (81972146), the
Department of Science and Technology of Sichuan Province (20YYJC3320), China
Postdoctoral Science Foundation (2020M673251), Health Commission of Sichuan
Province (20PJ034), and West China Hospital of Sichuan University (HX-2019-nCoV011 to Chengqi He, and 2019HXBH058 to Siyi Zhu). The funders played no role in the
design, conduct, or reporting of this study.

451 **Competing interests**

- 452 The authors declare that they have no competing interests.
- 453
- 454

455 **References**

- 456 1. Liang W-h, Guan W-j, Li C-c, Li Y-m, Liang H-r, Zhao Y, et al. Clinical characteristics and
- 457 outcomes of hospitalised patients with COVID-19 treated in Hubei (epicentre) and outside Hubei
- 458 (non-epicentre): a nationwide analysis of China. European Respiratory Journal. 2020;55(6).
- 459 2. Center for Evidence Based Medicine (CEBM). Global Covid-19 Case Fatality Rates (last
- updated on June 6 2020) 2020 [cited 2020 Aug 10]. Available from:
- 461 <u>https://www.cebm.net/covid-19/global-covid-19-case-fatality-rates/</u>.
- 462 3. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical characteristics of
- 463 coronavirus disease 2019 in China. New England Journal of Medicine. 2020.
- 464 4. Tucci V, Moukaddam N, Meadows J, Shah S, Galwankar SC, Kapur GB. The Forgotten
- 465 Plague: Psychiatric Manifestations of Ebola, Zika, and Emerging Infectious Diseases. Journal of
- 466 global infectious diseases. 2017;9(4):151-6. Epub 2018/01/06. doi: 10.4103/jgid.jgid_66_17.
- 467 PubMed PMID: 29302150; PubMed Central PMCID: PMC5750439.
- 468 5. Griffiths J, Hatch RA, Bishop J, Morgan K, Jenkinson C, Cuthbertson BH, et al. An
- 469 exploration of social and economic outcome and associated health-related quality of life after
- 470 critical illness in general intensive care unit survivors: a 12-month follow-up study. Crit Care.

471 2013;17(3):R100. Epub 2013/05/30. doi: 10.1186/cc12745. PubMed PMID: 23714692; PubMed
472 Central PMCID: PMC3706775.

Wunderink RG, Waterer G. Advances in the causes and management of community
acquired pneumonia in adults. BMJ. 2017;358:j2471. Epub 2017/07/12. doi: 10.1136/bmj.j2471.
PubMed PMID: 28694251.

476 7. Fraser E. Long term respiratory complications of covid-19. British Medical Journal
477 Publishing Group; 2020.

478 8. Gonzalez-Jaramillo N, Low N, Franco OH. The double burden of disease of COVID-19 in

479 cardiovascular patients: overlapping conditions could lead to overlapping treatments. European

480 journal of epidemiology. 2020;35(4):335.

481 9. James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and

482 national incidence, prevalence, and years lived with disability for 354 diseases and injuries for

483 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease

484 Study 2017. The Lancet. 2018;392(10159):1789-858.

485 10. Kyu HH, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and

486 national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life

487 expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the

488 Global Burden of Disease Study 2017. The Lancet. 2018;392(10159):1859-922.

489 11. Tansey CM, Louie M, Loeb M, Gold WL, Muller MP, de Jager J, et al. One-year outcomes

490 and health care utilization in survivors of severe acute respiratory syndrome. Archives of

491 internal medicine. 2007;167(12):1312-20.

- 492 12. Brooks SK, Webster RK, Smith LE, Woodland L, Wessely S, Greenberg N, et al. The
- 493 psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet.
- 494 2020. Epub 2020/03/01. doi: 10.1016/S0140-6736(20)30460-8. PubMed PMID: 32112714.
- 495 13. Siu JY. The SARS-associated stigma of SARS victims in the post-SARS era of Hong Kong.
- 496 Qualitative health research. 2008;18(6):729-38. Epub 2008/05/27. doi:
- 497 10.1177/1049732308318372. PubMed PMID: 18503014.
- 498 14. National Health Commission of the PR China [国家卫生健康委员会]. Diagnostic criteria
- 499 of the Novel Coronavirus Pneumonia Diagnosis and Treatment Program (Trial Version 7) [in
- 500 Chinese; 关于印发新型冠状病毒肺炎诊疗方案(试行第七版)的通知] 2020 [cited 2020
- 501 March 25]. Available from:
- 502 http://www.nhc.gov.cn/xcs/zhengcwj/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml.
- 503 15. Tong AY, Man DW. The validation of the Hong Kong Chinese version of the Lawton
- 504 Instrumental Activities of Daily Living Scale for institutionalized elderly persons. OTJR:
- 505 Occupation, Participation and Health. 2002;22(4):132-42.
- 16. Wade DT, Hewer RL. Functional abilities after stroke: measurement, natural history and
- prognosis. Journal of neurology, neurosurgery, and psychiatry. 1987;50(2):177-82. Epub
- 508 1987/02/01. doi: 10.1136/jnnp.50.2.177. PubMed PMID: 3572432; PubMed Central PMCID:
- 509 PMC1031489.
- 510 17. Sze KH, Wong E, Or KH, Lum CM, Woo J. Factors predicting stroke disability at discharge:
- 511 a study of 793 Chinese. Archives of physical medicine and rehabilitation. 2000;81(7):876-80.
- 512 Epub 2000/07/15. doi: 10.1053/apmr.2000.6279. PubMed PMID: 10895998.

513 18. Zung WW. A Rating Instrument For Anxiety Disorders. Psychosomatics. 1971;12(6):371-

514 **9**.

- 515 19. Dunstan DA, Scott N. Norms for Zung's Self-rating Anxiety Scale. BMC psychiatry.
- 516 2020;20(1):90. Epub 2020/03/01. doi: 10.1186/s12888-019-2427-6. PubMed PMID: 32111187;
- 517 PubMed Central PMCID: PMC7048044.
- 518 20. Zou G. A modified poisson regression approach to prospective studies with binary data.
- 519 American journal of epidemiology. 2004;159(7):702-6.
- 520 21. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of
- 521 Coronavirus Disease 2019 in China. The New England journal of medicine. 2020. Epub

522 2020/02/29. doi: 10.1056/NEJMoa2002032. PubMed PMID: 32109013.

523 22. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and

524 Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice

525 Guideline of the American Thoracic Society and Infectious Diseases Society of America.

526 American journal of respiratory and critical care medicine. 2019;200(7):e45-e67. Epub

527 2019/10/02. doi: 10.1164/rccm.201908-1581ST. PubMed PMID: 31573350; PubMed Central

528 PMCID: PMC6812437.

529 23. Alger HM, Williams Iv JH, Walchok JG, Bolles MM, Fonarow GC, Rutan C. The Role of Data

Registries in the Time of COVID-19. Circulation Cardiovascular quality and outcomes. 2020. Epub

531 2020/04/17. doi: 10.1161/circoutcomes.120.006766. PubMed PMID: 32298145.

532 24. Cao W-C, De Vlas SJ, Richardus JH. The severe acute respiratory syndrome epidemic in

533 mainland China dissected. Infectious disease reports. 2011;3(1).

534 25. Batawi S, Tarazan N, Al-Raddadi R, Al Qasim E, Sindi A, Johni SA, et al. Quality of life

reported by survivors after hospitalization for Middle East respiratory syndrome (MERS). Health

536 and quality of life outcomes. 2019;17(1):101.

537 26. Lee S, Chan LY, Chau AM, Kwok KP, Kleinman A. The experience of SARS-related stigma

538 at Amoy Gardens. Soc Sci Med. 2005;61(9):2038-46. Epub 2005/05/26. doi:

539 10.1016/j.socscimed.2005.04.010. PubMed PMID: 15913861.

540 27. Ryrso CK, Godtfredsen NS, Kofod LM, Lavesen M, Mogensen L, Tobberup R, et al. Lower

541 mortality after early supervised pulmonary rehabilitation following COPD-exacerbations: a

542 systematic review and meta-analysis. BMC pulmonary medicine. 2018;18(1):154. Epub

543 2018/09/17. doi: 10.1186/s12890-018-0718-1. PubMed PMID: 30219047; PubMed Central

544 PMCID: PMC6139159.

545 28. Vogiatzis I, Rochester CL, Spruit MA, Troosters T, Clini EM. Increasing implementation

546 and delivery of pulmonary rehabilitation: key messages from the new ATS/ERS policy statement.

547 The European respiratory journal. 2016;47(5):1336-41. Epub 2016/05/02. doi:

548 10.1183/13993003.02151-2015. PubMed PMID: 27132269.

549 29. Chen L, Liu W, Zhang Q, Xu K, Ye G, Wu W, et al. RNA based mNGS approach identifies a

novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak.

551 Emerging Microbes and Infections. 2020;9(1):313-9. PubMed PMID: 2004238813.

552 30. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical

characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive

554 study. Lancet. 2020;395(10223):507-13. Epub 2020/02/03. doi: 10.1016/s0140-6736(20)30211-

555 7. PubMed PMID: 32007143; PubMed Central PMCID: PMCPMC7135076.

556 31. Lai J, Ma S, Wang Y, Cai Z, Hu J, Wei N, et al. Factors Associated With Mental Health

- 557 Outcomes Among Health Care Workers Exposed to Coronavirus Disease 2019. JAMA network
- 558 open. 2020;3(3):e203976. Epub 2020/03/24. doi: 10.1001/jamanetworkopen.2020.3976.
- 559 PubMed PMID: 32202646; PubMed Central PMCID: PMCPMC7090843.
- 560 32. Mak IWC, Chu CM, Pan PC, Yiu MGC, Chan VL. Long-term psychiatric morbidities among
- 561 SARS survivors. General hospital psychiatry. 2009;31(4):318-26.
- 562 33. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality
- of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet.
- 564 2020;395(10229):1054-62. Epub 2020/03/15. doi: 10.1016/S0140-6736(20)30566-3. PubMed
 565 PMID: 32171076.
- 566 34. Guan W-j, Liang W-h, Zhao Y, Liang H-r, Chen Z-s, Li Y-m, et al. Comorbidity and its

impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. European Respiratory
Journal. 2020;55(5).

- 35. WHO. International Classification of Functioning, Disability, and Health. Geneva: WHO
 Press; 2001.
- 571 36. Armitage R, Nellums LB. The COVID-19 response must be disability inclusive. The Lancet
- 572 Public Health. 2020;5(5):e257.
- 573 37. WHO. Disability considerations during the COVID-19 outbreak: World Health
- 574 Organization; 2020 [cited 2020 Aug 10]. Available from:
- 575 <u>https://apps.who.int/iris/bitstream/handle/10665/332015/WHO-2019-nCov-Disability-2020.1-</u>
- 576 <u>eng.pdf</u>.

- 577 38. Solomon MZ, Wynia MK, Gostin LO. Covid-19 crisis triage—optimizing health outcomes
- and disability rights. New England Journal of Medicine. 2020.
- 579 39. Giummarra MJ, Lennox A, Dali G, Costa B, Gabbe BJ. Early psychological interventions for
- 580 posttraumatic stress, depression and anxiety after traumatic injury: A systematic review and
- 581 meta-analysis. Clinical psychology review. 2018;62:11-36. Epub 2018/05/14. doi:
- 582 10.1016/j.cpr.2018.05.001. PubMed PMID: 29754102.
- 583 40. Zhang L, Hu W, Cai Z, Liu J, Wu J, Deng Y, et al. Early mobilization of critically ill patients
- in the intensive care unit: A systematic review and meta-analysis. PLoS One.
- 585 2019;14(10):e0223185. Epub 2019/10/04. doi: 10.1371/journal.pone.0223185. PubMed PMID:
- 586 31581205; PubMed Central PMCID: PMC6776357.
- 587 41. Xiao Y, Zhao K, Ma ZX, Li X, Qiu YP. Integrated medical rehabilitation delivery in China.
- 588 Chronic diseases and translational medicine. 2017;3(2):75-81. Epub 2017/10/25. doi:
- 589 10.1016/j.cdtm.2017.02.003. PubMed PMID: 29063059; PubMed Central PMCID: PMC5627700.

590

592 Supporting information

593	Table S1. Outcome: One or more IADL problems (Lawton IADL scale, at least one
594	item endorsed) ^{&} . ^{&} n= 431 for adjusted model and unadjusted model for age, n= 432 for
595	all other models. RR = Risk Ratio. CI = Confidence Interval.
596	
597	Table S2. Outcome: At least moderate ADL dependence (Barthel Index, < 75) ^{&} . $^{\&}n=$
598	431 for adjusted model and unadjusted model for age, n= 432 for all other models. RR =
599	Risk Ratio. CI = Confidence Interval.
600	
601	Table S3. Outcome: Anxiety (Zung's self-reported anxiety scale, raw score < 40) ^{&} .
602	$^{\&}$ n=407 for adjusted model and n=407 for unadjusted model for length of stay, n= 431 for
603	unadjusted model for age, n= 432 for all other models. RR = Risk Ratio. CI = Confidence
604	Interval.
605	
606	
607	



1. Presence of IADL limitations (at least one)







